Advertisement
Free access | 10.1172/JCI106939
Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut 06510
Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06510
Find articles by Nixon, P. in: JCI | PubMed | Google Scholar
Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut 06510
Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06510
Find articles by Bertino, J. in: JCI | PubMed | Google Scholar
Published June 1, 1972 - More info
The possible role of cobalamins in the utilization of serum methyltetrahydrofolate has been investigated by means of radiolabeled methyltetrahydrofolate in subjects suffering from pernicious anemia. After intravenous administration, methyltetrahydrofolate-3H (SA 11,500 Ci/mole; dose 0.05 μg/kg) was cleared from the serum to tissues of B12-deficient subjects half as fast as after the same subjects had received vitamin B12 therapy. B12 deficiency was also associated with an increased rate of renal excretion of methyltetrahydrofolate or its derivatives, and a decreased rate of renal metabolism of methyltetrahydrofolate to other urinary folate derivatives.
Intravenously administered methyl-14C-tetrahydrofolate-3H at a higher dose (5 μg/kg) caused a severalfold elevation of the total serum folate concentration and, in B12-deficient subjects, it did not disappear from the serum significantly more slowly although its urinary excretion was significantly increased.
These results indicate that there is some cobalamin requirement for the utilization of serum methyltetrahydrofolate and verify one prediction of the “methyltetrahydrofolate trap” explanation for the megaloblastosis of B12 deficiency.